Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Last Close
Feb 11  •  04:00PM ET
0.8130
Dollar change
-0.0556
Percentage change
-6.40
%
Index- P/E43.95 EPS (ttm)0.02 Insider Own20.44% Shs Outstand34.04M Perf Week-3.09%
Market Cap30.25M Forward P/E- EPS next Y-0.41 Insider Trans-4.09% Shs Float29.60M Perf Month-15.31%
Enterprise Value79.31M PEG- EPS next Q0.03 Inst Own12.28% Short Float5.17% Perf Quarter-22.57%
Income0.10M P/S0.19 EPS this Y15.38% Inst Trans3.50% Short Ratio4.12 Perf Half Y-60.34%
Sales162.61M P/B0.38 EPS next Y46.75% ROA-13.88% Short Interest1.53M Perf YTD-12.59%
Book/sh2.14 P/C0.88 EPS next 5Y- ROE-45.88% 52W High2.68 -69.66% Perf Year-66.68%
Cash/sh0.92 P/FCF- EPS past 3/5Y- - ROIC0.09% 52W Low0.77 5.11% Perf 3Y-88.04%
Dividend Est.- EV/EBITDA- Sales past 3/5Y-21.83% -12.32% Gross Margin31.13% Volatility6.97% 5.76% Perf 5Y-
Dividend TTM- EV/Sales0.49 EPS Y/Y TTM101.30% Oper. Margin-15.55% ATR (14)0.06 Perf 10Y-
Dividend Ex-Date- Quick Ratio0.89 Sales Y/Y TTM-25.44% Profit Margin0.06% RSI (14)37.72 Recom3.00
Dividend Gr. 3/5Y- - Current Ratio0.89 EPS Q/Q-469.32% SMA20-9.14% Beta3.43 Target Price1.00
Payout- Debt/Eq1.09 Sales Q/Q-27.99% SMA50-13.55% Rel Volume0.28 Prev Close0.87
Employees- LT Debt/Eq0.53 EarningsNov 06 AMC SMA200-50.21% Avg Volume371.05K Price0.81
IPOMar 05, 2021 Option/ShortYes / Yes EPS/Sales Surpr.-233.33% -15.25% Trades Volume103,591 Change-6.40%
Date Action Analyst Rating Change Price Target Change
Nov-21-25Downgrade Craig Hallum Buy → Hold $1
Nov-22-22Downgrade Cowen Outperform → Market Perform $3 → $2
Aug-11-22Downgrade BofA Securities Neutral → Underperform $4.50 → $2
Feb-04-22Initiated BofA Securities Neutral $5
Jan-12-22Initiated Craig Hallum Buy $7.50
Jan-10-22Initiated Cowen Outperform $7
Jan-22-26 04:15PM
Nov-06-25 04:10PM
Oct-15-25 10:06AM
Sep-11-25 04:14PM
03:04PM
03:41AM Loading…
Aug-08-25 03:41AM
Aug-07-25 04:15PM
Jul-14-25 04:30PM
May-27-25 09:00AM
May-09-25 10:00AM
May-08-25 03:27AM
May-07-25 03:14PM
03:13PM
09:00AM
Apr-30-25 03:00PM
10:53AM Loading…
Apr-25-25 10:53AM
Apr-21-25 04:15PM
Apr-03-25 11:50AM
Mar-25-25 12:18PM
Mar-20-25 01:49PM
Mar-13-25 04:05PM
Feb-11-25 11:06AM
Dec-12-24 09:05AM
Nov-12-24 04:40PM
Oct-08-24 04:30PM
Aug-12-24 04:19PM
Jul-16-24 05:08PM
Jul-11-24 04:30PM
Jun-28-24 03:34PM
Jun-27-24 10:05AM
04:09PM Loading…
Jun-24-24 04:09PM
11:27AM
Jun-20-24 07:15AM
Jun-18-24 02:30PM
06:30AM
Jun-09-24 02:09PM
Jun-06-24 07:00AM
May-28-24 02:56PM
May-22-24 02:52PM
12:34PM
12:19PM
12:11PM
10:41AM
09:42AM
May-17-24 09:00AM
May-13-24 09:53PM
04:37PM
01:59PM
May-02-24 11:30AM
Apr-22-24 04:30PM
Apr-16-24 12:18PM
10:58AM
Mar-28-24 10:04AM
Mar-27-24 11:24AM
Mar-26-24 12:50PM
Mar-25-24 09:52PM
04:32PM
12:53PM
Mar-19-24 05:52PM
Feb-22-24 11:29AM
08:14AM
Feb-21-24 04:05PM
Feb-15-24 03:16PM
Nov-12-23 08:39AM
Nov-03-23 11:05AM
Nov-02-23 04:30PM
Oct-31-23 03:50PM
Oct-26-23 04:30PM
Sep-26-23 01:09PM
Sep-18-23 12:29PM
Sep-15-23 03:01AM
Aug-08-23 04:10PM
Jul-29-23 11:24AM
Jul-11-23 11:16AM
Jun-29-23 04:05PM
Jun-22-23 10:50AM
Jun-20-23 09:00AM
Jun-13-23 09:00PM
Jun-05-23 12:00PM
May-24-23 09:00AM
May-23-23 09:35AM
May-15-23 03:58PM
08:54AM
May-11-23 04:15PM
May-10-23 07:22AM
May-09-23 05:10PM
04:20PM
May-03-23 04:15PM
May-02-23 02:33PM
Apr-21-23 06:35PM
Apr-20-23 10:10PM
04:58PM
03:43PM
12:05PM
11:51AM
Apr-11-23 08:35AM
Mar-17-23 07:11PM
Mar-15-23 09:09AM
Mar-13-23 04:31PM
Feb-16-23 05:30AM
Buzzfeed, Inc. is an independent digital media company, which engages in engagement, distribution, and leveraging data. Its cross-platform network includes BuzzFeed Originals, which creates articles, lists, quizzes, and videos, BuzzFeed Media Brands, which consists of a portfolio of identity-driven lifestyle brands including Nifty, Goodful, As/Is, and Tasty, a social food network, BuzzFeed Studios, which produces original content across broadcast, cable, SVOD, film and digital platforms, and BuzzFeed News and HuffPost, which include reporting and investigative journalism, and BuzzFeed Commerce, which develops products and experiences, as well as licensing and other strategic partnerships. The company was founded by Jonah Peretti and John Johnson in November 2006 and is headquartered in New York, NY.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Rothstein AdamDirectorFeb 01 '26Option Exercise0.00101,3370841,038Feb 03 05:25 PM
COLEMAN GREGORYDirectorDec 01 '25Option Exercise0.0011,8970375,684Dec 03 06:24 PM
Rothstein AdamDirectorDec 01 '25Option Exercise0.0016,6560739,701Dec 03 06:24 PM
Rolle Janet LDirectorDec 01 '25Option Exercise0.0011,8970122,110Dec 03 06:24 PM
Arroyo DavidCLONov 11 '25Option Exercise0.0025,1440157,460Nov 13 08:40 PM
Omer MatthewCFONov 11 '25Option Exercise0.0060,2600356,127Nov 13 08:40 PM
Rolle Janet LDirectorSep 12 '25Sale2.0023,90747,912110,213Sep 17 05:09 PM
Acharia AngelaDirectorSep 12 '25Sale2.0156,378113,37611,870Sep 16 05:06 PM
Rolle Janet LOfficerSep 12 '25Proposed Sale2.0037,09274,184Sep 15 04:52 PM
Rothstein AdamDirectorSep 11 '25Sale2.00150,000300,660723,045Sep 12 06:50 PM
Acharia AngelaDirectorSep 08 '25Sale1.9425,00048,44068,248Sep 11 08:10 PM
Rothstein AdamBoard MemberSep 11 '25Proposed Sale1.99150,000299,223Sep 11 05:08 PM
Acharia AngelaDirectorSep 05 '25Sale1.871,2852,40393,248Sep 09 08:21 PM
Acharia AngelaDirectorSep 03 '25Sale1.8867,985127,81294,633Sep 05 04:50 PM
Acharia AngelaDirectorSep 04 '25Sale1.8810018894,533Sep 05 04:50 PM
Rolle Janet LDirectorSep 01 '25Option Exercise0.0011,8970134,120Sep 03 08:22 PM
Acharia AngelaDirectorSep 01 '25Option Exercise0.0011,8970162,618Sep 03 08:22 PM
COLEMAN GREGORYDirectorSep 01 '25Option Exercise0.0011,8970363,787Sep 03 08:22 PM
Rothstein AdamDirectorSep 01 '25Option Exercise0.0016,6550873,045Sep 03 08:22 PM
Arroyo DavidCLOAug 12 '25Option Exercise0.0025,4730142,584Aug 14 06:27 PM
Omer MatthewCFOAug 12 '25Option Exercise0.0061,3370317,815Aug 14 06:27 PM
Johnson John S. IIIMember of 10% GroupJul 24 '25Sale2.4550,000122,3101,041,195Jul 25 06:16 PM
Rolle Janet LDirectorJun 16 '25Sale2.1124,47451,723122,223Jun 17 05:59 PM
Rothstein AdamDirectorJun 01 '25Option Exercise0.0016,6560856,390Jun 03 05:50 PM
COLEMAN GREGORYDirectorJun 01 '25Option Exercise0.0011,8970351,890Jun 03 05:50 PM
Acharia AngelaDirectorJun 01 '25Option Exercise0.0011,8970150,721Jun 03 05:49 PM
Rolle Janet LDirectorJun 01 '25Option Exercise0.0011,8970146,697Jun 03 05:49 PM
Omer MatthewCFOMay 09 '25Option Exercise0.00120,6780299,547May 13 07:44 PM
Arroyo DavidCLOMay 10 '25Option Exercise0.0025,8440127,529May 13 07:44 PM
KERINS PATRICK J10% OwnerMar 14 '25Sale2.26273,246618,3833,401,499Mar 14 06:02 PM
KERINS PATRICK J10% OwnerMar 13 '25Sale2.0161,448123,7693,674,745Mar 14 06:02 PM
KERINS PATRICK J10% OwnerMar 12 '25Sale1.9828,27255,8543,736,193Mar 14 06:02 PM
NEW ENTERPRISE ASSOCIATES 13 L10% OwnerMar 14 '25Sale2.26273,246618,3833,401,499Mar 14 05:58 PM
NEW ENTERPRISE ASSOCIATES 13 L10% OwnerMar 13 '25Sale2.0161,448123,7693,674,745Mar 14 05:58 PM
NEW ENTERPRISE ASSOCIATES 13 L10% OwnerMar 12 '25Sale1.9828,27255,8543,736,193Mar 14 05:58 PM
KERINS PATRICK J10% OwnerMar 07 '25Sale2.0633,84869,6023,778,094Mar 11 07:25 PM
KERINS PATRICK J10% OwnerMar 11 '25Sale1.9513,62926,6203,764,465Mar 11 07:25 PM
NEW ENTERPRISE ASSOCIATES 13 L10% OwnerMar 07 '25Sale2.0633,84869,6023,778,094Mar 11 06:53 PM
NEW ENTERPRISE ASSOCIATES 13 L10% OwnerMar 11 '25Sale1.9513,62926,6203,764,465Mar 11 06:53 PM
Omer MatthewCFOMar 05 '25Option Exercise0.001,6660179,554Mar 07 07:57 PM
Arroyo DavidCLOMar 05 '25Option Exercise0.0025,1440113,206Mar 07 07:56 PM
KERINS PATRICK J10% OwnerMar 06 '25Sale2.1011,12723,3723,811,942Mar 06 09:08 PM
KERINS PATRICK J10% OwnerMar 05 '25Sale2.048,96618,2663,823,069Mar 06 09:08 PM
KERINS PATRICK J10% OwnerMar 04 '25Sale2.071,4382,9783,832,035Mar 06 09:08 PM
NEW ENTERPRISE ASSOCIATES 13 L10% OwnerMar 06 '25Sale2.1011,12723,3723,811,942Mar 06 09:05 PM
NEW ENTERPRISE ASSOCIATES 13 L10% OwnerMar 05 '25Sale2.048,96618,2663,823,069Mar 06 09:05 PM
NEW ENTERPRISE ASSOCIATES 13 L10% OwnerMar 04 '25Sale2.071,4382,9783,832,035Mar 06 09:05 PM
Rolle Janet LDirectorMar 01 '25Option Exercise0.0011,8960134,800Mar 04 06:54 PM
Rothstein AdamDirectorMar 01 '25Option Exercise0.0016,6550839,734Mar 04 06:53 PM
COLEMAN GREGORYDirectorMar 01 '25Option Exercise0.0011,8960339,993Mar 04 06:53 PM
Acharia AngelaDirectorMar 01 '25Option Exercise0.0011,8960138,824Mar 04 06:53 PM
Last Close
Feb 11  •  04:00PM ET
5.25
Dollar change
-0.39
Percentage change
-6.91
%
SGMT Sagimet Biosciences Inc daily Stock Chart
Index- P/E- EPS (ttm)-1.79 Insider Own19.07% Shs Outstand31.00M Perf Week-13.65%
Market Cap162.76M Forward P/E- EPS next Y-1.92 Insider Trans-0.63% Shs Float26.32M Perf Month-15.87%
Enterprise Value46.19M PEG- EPS next Q-0.43 Inst Own33.04% Short Float12.94% Perf Quarter-36.97%
Income-57.67M P/S- EPS this Y-14.92% Inst Trans-1.91% Short Ratio5.21 Perf Half Y-45.03%
Sales0.00M P/B1.43 EPS next Y-15.20% ROA-38.04% Short Interest3.41M Perf YTD-11.32%
Book/sh3.67 P/C1.39 EPS next 5Y-12.65% ROE-39.78% 52W High11.41 -53.99% Perf Year11.23%
Cash/sh3.76 P/FCF- EPS past 3/5Y-8.32% -16.85% ROIC-48.36% 52W Low1.73 203.47% Perf 3Y-
Dividend Est.- EV/EBITDA- Sales past 3/5Y- - Gross Margin- Volatility8.64% 7.79% Perf 5Y-
Dividend TTM- EV/Sales- EPS Y/Y TTM-38.23% Oper. Margin- ATR (14)0.47 Perf 10Y-
Dividend Ex-Date- Quick Ratio13.04 Sales Y/Y TTM-100.00% Profit Margin- RSI (14)39.78 Recom1.18
Dividend Gr. 3/5Y- - Current Ratio13.04 EPS Q/Q12.58% SMA20-11.84% Beta3.43 Target Price26.90
Payout- Debt/Eq0.00 Sales Q/Q- SMA50-13.02% Rel Volume1.07 Prev Close5.64
Employees14 LT Debt/Eq0.00 EarningsNov 13 BMO SMA200-22.99% Avg Volume654.08K Price5.25
IPOJul 14, 2023 Option/ShortYes / Yes EPS/Sales Surpr.-3.63% - Trades Volume702,902 Change-6.91%
Date Action Analyst Rating Change Price Target Change
Feb-03-26Initiated Guggenheim Buy $27
Jan-28-26Initiated Barclays Equal Weight $8
Aug-11-25Initiated Wedbush Outperform $28
Aug-07-25Resumed H.C. Wainwright Buy $29
Jul-24-25Initiated Canaccord Genuity Buy $28
Dec-06-24Initiated Oppenheimer Outperform $30
Nov-12-24Initiated UBS Buy $12
Jun-28-24Downgrade Goldman Buy → Neutral $23 → $6
May-02-24Initiated H.C. Wainwright Buy $32
Mar-25-24Initiated Leerink Partners Outperform $26
Feb-05-26 07:00AM
Feb-03-26 03:27PM
09:34AM
Feb-02-26 07:00AM
Jan-08-26 07:00AM
07:00AM Loading…
Dec-18-25 07:00AM
Dec-17-25 07:00AM
Dec-10-25 07:03AM
Dec-09-25 04:05PM
Nov-20-25 07:00AM
Nov-13-25 07:30AM
Nov-10-25 07:00AM
Oct-24-25 07:00AM
Oct-15-25 12:00PM
Oct-14-25 07:00AM
07:00AM Loading…
Oct-07-25 07:00AM
Oct-01-25 07:00AM
Sep-24-25 07:00AM
Sep-17-25 07:00AM
Sep-16-25 09:35AM
Sep-10-25 07:00AM
Aug-26-25 07:00AM
Aug-20-25 12:00PM
09:35AM
Aug-13-25 07:30AM
Aug-07-25 09:56AM
Aug-05-25 07:00AM
Jun-11-25 12:00PM
Jun-09-25 09:55AM
07:00AM
07:02AM Loading…
Jun-06-25 07:02AM
Jun-04-25 08:28AM
05:00AM
May-22-25 08:00AM
May-08-25 06:00AM
Apr-23-25 08:00AM
Mar-12-25 07:30AM
Mar-11-25 08:00AM
Feb-25-25 08:25AM
Feb-22-25 05:24PM
Feb-19-25 08:00AM
Jan-06-25 08:00AM
Dec-15-24 06:04AM
Nov-26-24 08:00AM
Nov-18-24 08:00AM
Nov-14-24 08:00AM
Nov-12-24 06:30AM
Nov-07-24 07:30AM
Oct-29-24 07:00AM
Oct-16-24 07:00AM
Oct-11-24 07:00AM
Oct-01-24 07:00AM
12:05AM
Sep-12-24 07:30AM
Sep-04-24 08:00AM
Aug-14-24 08:00AM
Aug-01-24 08:00AM
Jun-10-24 08:00AM
Jun-06-24 05:00AM
May-16-24 08:00AM
May-15-24 12:53PM
08:00AM
May-07-24 08:00AM
May-06-24 08:00AM
Apr-22-24 08:00AM
Mar-27-24 04:01PM
Mar-25-24 07:00AM
06:15AM
Feb-29-24 08:00AM
Jan-25-24 08:58PM
Jan-23-24 05:45PM
Jan-22-24 11:10PM
07:00AM
Dec-04-23 08:00AM
Nov-28-23 08:00AM
Nov-22-23 08:00AM
Nov-13-23 08:00AM
Nov-10-23 08:30AM
Oct-24-23 11:00AM
Oct-18-23 04:05PM
Sep-27-23 04:05PM
Aug-29-23 10:21AM
Aug-21-23 04:02PM
Aug-15-23 04:04PM
Aug-08-23 10:02AM
Jul-20-23 04:05PM
Jul-13-23 09:10PM
Sagimet Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics for the treatment of infectious diseases. Its lead drug candidate, denifanstat, is an oral, once-daily pill and selective fatty acid synthase (FASN) inhibitor in development for the treatment of nonalcoholic steatohepatitis (NASH). The company was founded by Urs F. Greber, Ari Helenius, and Lucas Pelkmans on December 19, 2006 and is headquartered in San Mateo, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Kemble GeorgeExecutive ChairmanNov 20 '25Sale7.6937,688289,97981,005Nov 21 06:13 PM
GEORGE KEMBLEDirectorNov 20 '25Proposed Sale7.8537,688295,851Nov 20 04:21 PM
Happel DavidPresident & CEOJul 21 '25Sale9.1365,478598,115689,722Jul 23 04:16 PM
Martins Eduardo BrunoChief Medical OfficerJul 21 '25Sale9.138,27775,607106,936Jul 23 04:15 PM
Rozek ElizabethGeneral Counsel and CCOJul 21 '25Sale9.1310,78098,471183,726Jul 23 04:14 PM